Resumen

MEIRELES, Sara et al. Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. Arq Med [online]. 2015, vol.29, n.1, pp.02-05. ISSN 2183-2447.

Background: Until recently, patients with metastatic castration-resistant prostate cancer (mCRPC) had limited therapeutic options once they became refractory to docetaxel chemotherapy. Cabazitaxel is a new generation taxane with benefit on overall survival of these patients. The authors report the clinical experience from the institution regarding to efficacy and tolerability of this agent in treatment of mCRPC after docetaxel. Methods: Retrospective review of patients with mCRPC who started cabazitaxel treatment between January 2011 and January 2012 in Centro Hospitalar São João. Survival analysis was performed by Kaplan-Meier method. Results: twelve patients were submitted to cabazitaxel treatment. The median age was 70 years old [60-75] and 10 patients had ECOG performance status 0-1. PSA response rate was 64% and PSA reduction rate > 50% was 57%. After a follow-up of 14 months, the progression rate was 55% with a median time to progression of 7 months. The median of progression free survival (PFS) and overall survival (OS) was 8 months (CI 95% 3.4-12.7) and 14 months (CI 95% 7.3-20.2). The 1-year PFS and OS was 40% and 58% respectively. The most common adverse events were anemia (83%), neutropenia (25%) and diarrhea (25%). Conclusion: Our experience shows that cabazitaxel is a therapeutic option with benefit in refractory disease to docetaxel chemotherapy with response rates and tolerability comparable to its approval study.

Palabras clave : prostate cancer; metastatic; cabazitaxel.

        · resumen en Portugués     · texto en Portugués     · Portugués ( pdf )